ErbB-2 nuclear function in breast cancer growth, metastasis and resistance to therapy

The PI3K/AKT Pathway as a Target for Cancer Treatment

(2016) Ingrid A. Mayer et al.   Annual Review of Medicine

Proteolytic cleavage, trafficking, and functions of nuclear receptor tyrosine kinases

(2015) Mei-Kuang Chen et al.   FEBS Journal

MicroRNA expression as risk biomarker of breast cancer metastasis: a pilot retrospective case-cohort study

(2014) Augusto LF Marino et al.   BMC CANCER

HER2-positive advanced breast cancer: optimizing patient outcomes and opportunities for drug development

(2014) J C Singh et al.   BRITISH JOURNAL OF CANCER

Targeting ErbB-2 nuclear localization and function inhibits breast cancer growth and overcomes trastuzumab resistance

(2014) R I Cordo Russo et al.   ONCOGENE

Mapping C-Terminal Transactivation Domains of the Nuclear HER Family Receptor Tyrosine Kinase HER3

(2013) Toni M. Brand et al.   PLoS One

Receptor Tyrosine Kinases in the Nucleus

(2013) G. Carpenter et al.   Cold Spring Harbor Perspectives in Biology

Role of STAT3 in Cancer Metastasis and Translational Advances

(2013) Mohammad Zahid Kamran et al.   Biomed Research International

Clinical relevance of ErbB-2/HER2 nuclear expression in breast cancer

(2012) Roxana Schillaci et al.   BMC CANCER

The Atypical Histone MacroH2A1.2 Interacts with HER-2 Protein in Cancer Cells

(2012) Xiufen Li et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

Membrane-bound Trafficking Regulates Nuclear Transport of Integral Epidermal Growth Factor Receptor (EGFR) and ErbB-2

(2012) Ying-Nai Wang et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

DNA Damage Induces NF-κB-dependent MicroRNA-21 Up-regulation and Promotes Breast Cancer Cell Invasion

(2012) Jixiao Niu et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

The hard facts

(2012) Amy Maxmen   NATURE

Improving Treatment of HER2-Positive Cancers: Opportunities and Challenges

(2012) H. M. Stern   Science Translational Medicine

Progestin drives breast cancer growth by inducing p21CIP1 expression through the assembly of a transcriptional complex among Stat3, progesterone receptor and ErbB-2

(2012) María C. Diaz Flaqué et al.   STEROIDS

Nuclear functions and subcellular trafficking mechanisms of the epidermal growth factor receptor family

(2012) Ying-Nai Wang et al.   Cell and Bioscience

Nuclear ErbB2 Enhances Translation and Cell Growth by Activating Transcription of Ribosomal RNA Genes

(2011) L.-Y. Li et al.   CANCER RESEARCH

Trastuzumab Has Preferential Activity against Breast Cancers Driven by HER2 Homodimers

(2011) R. Ghosh et al.   CANCER RESEARCH

MicroRNA miR-21 Regulates the Metastatic Behavior of B16 Melanoma Cells

(2011) Chuan He Yang et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

Re-expression of miR-21 contributes to migration and invasion by inducing epithelial-mesenchymal transition consistent with cancer stem cell characteristics in MCF-7 cells

(2011) Mingli Han et al.   MOLECULAR AND CELLULAR BIOCHEMISTRY

Transcriptional and posttranslational up-regulation of HER3 (ErbB3) compensates for inhibition of the HER2 tyrosine kinase

(2011) J. T. Garrett et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

A Major Role of p95/611-CTF, a Carboxy-Terminal Fragment of HER2, in the Down-modulation of the Estrogen Receptor in HER2-Positive Breast Cancers

(2010) J. L. Parra-Palau et al.   CANCER RESEARCH

Constitutively Active Stat3 Enhances Neu-Mediated Migration and Metastasis in Mammary Tumors via Upregulation of Cten

(2010) I. Barbieri et al.   CANCER RESEARCH

The Translocon Sec61β Localized in the Inner Nuclear Membrane Transports Membrane-embedded EGF Receptor to the Nucleus

(2010) Ying-Nai Wang et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

Lapatinib, a dual HER1/HER2 tyrosine kinase inhibitor, augments basal cleavage of HER2 extracellular domain (ECD) to inhibit HER2-driven cancer cell growth

(2010) Alejandro Vazquez-Martin et al.   JOURNAL OF CELLULAR PHYSIOLOGY

MicroRNA-21 regulates breast cancer invasion partly by targeting tissue inhibitor of metalloproteinase 3 expression

(2010) Bao Song et al.   JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH

Progesterone Receptor Induces ErbB-2 Nuclear Translocation To Promote Breast Cancer Growth via a Novel Transcriptional Effect: ErbB-2 Function as a Coactivator of Stat3

(2010) W. Beguelin et al.   MOLECULAR AND CELLULAR BIOLOGY

STAT3 Activation of miR-21 and miR-181b-1 via PTEN and CYLD Are Part of the Epigenetic Switch Linking Inflammation to Cancer

(2010) Dimitrios Iliopoulos et al.   MOLECULAR CELL

Nuclear trafficking of the epidermal growth factor receptor family membrane proteins

(2010) Y-N Wang et al.   ONCOGENE

Ligand-Independent HER2/HER3/PI3K Complex Is Disrupted by Trastuzumab and Is Effectively Inhibited by the PI3K Inhibitor GDC-0941

(2009) Teemu T. Junttila et al.   CANCER CELL

Identification of a Stat3-Dependent Transcription Regulatory Network Involved in Metastatic Progression

(2009) J. J. Ranger et al.   CANCER RESEARCH

The role of HER2 in early breast cancer metastasis and the origins of resistance to HER2-targeted therapies

(2009) Jaclyn A. Freudenberg et al.   EXPERIMENTAL AND MOLECULAR PATHOLOGY

Up-regulation of miR-21 by HER2/neuSignaling Promotes Cell Invasion

(2009) Tzu-Hsuan Huang et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

HER2 Carboxyl-terminal Fragments Regulate Cell Migration and Cortactin Phosphorylation

(2009) Jesús García-Castillo et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

A Naturally Occurring HER2 Carboxy-Terminal Fragment Promotes Mammary Tumor Growth and Metastasis

(2009) K. Pedersen et al.   MOLECULAR AND CELLULAR BIOLOGY

Molecular predictors of response to trastuzumab and lapatinib in breast cancer

(2009) Francisco J. Esteva et al.   Nature Reviews Clinical Oncology

The HER-2 Receptor and Breast Cancer: Ten Years of Targeted Anti-HER-2 Therapy and Personalized Medicine

(2009) J. S. Ross et al.   ONCOLOGIST

Lapatinib, a Dual EGFR and HER2 Tyrosine Kinase Inhibitor, Downregulates Thymidylate Synthase by Inhibiting the Nuclear Translocation of EGFR and HER2

(2009) Hwang-Phill Kim et al.   PLoS One

Structural analysis of the catalytically inactive kinase domain of the human EGF receptor 3

(2009) N. Jura et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Programmed Cell Death 4 inhibits breast cancer cell invasion by increasing Tissue Inhibitor of Metalloproteinases-2 expression

(2008) René Nieves-Alicea et al.   BREAST CANCER RESEARCH AND TREATMENT

The growth inhibitory effect of lapatinib, a dual inhibitor of EGFR and HER2 tyrosine kinase, in gastric cancer cell lines

(2008) Jin Won Kim et al.   CANCER LETTERS

MicroRNA-21 targets tumor suppressor genes in invasion and metastasis

(2008) Shuomin Zhu et al.   CELL RESEARCH

Lapatinib: A dual inhibitor of human epidermal growth factor receptor tyrosine kinases

(2008) P MEDINA et al.   CLINICAL THERAPEUTICS

ShcA signalling is essential for tumour progression in mouse models of human breast cancer

(2008) Josie Ursini-Siegel et al.   EMBO JOURNAL

Cyclooxygenase-2 predicts adverse effects of tamoxifen: a possible mechanism of role for nuclear HER2 in breast cancer patients

(2008) M. F Dillon et al.   ENDOCRINE-RELATED CANCER

EGFR family: Structure physiology signalling and therapeutic targets†

(2008) Antony W. Burgess   GROWTH FACTORS

All EGF(ErbB) receptors have preformed homo- and heterodimeric structures in living cells

(2008) R.-H. Tao et al.   JOURNAL OF CELL SCIENCE

The epidermal growth factor receptor ligands at a glance

(2008) Marlon R. Schneider et al.   JOURNAL OF CELLULAR PHYSIOLOGY

Activation of Stat3 by Heregulin/ErbB-2 through the Co-Option of Progesterone Receptor Signaling Drives Breast Cancer Growth

(2008) C. J. Proietti et al.   MOLECULAR AND CELLULAR BIOLOGY

Lapatinib, a HER2 tyrosine kinase inhibitor, induces stabilization and accumulation of HER2 and potentiates trastuzumab-dependent cell cytotoxicity

(2008) M Scaltriti et al.   ONCOGENE

MicroRNA miR-21 overexpression in human breast cancer is associated with advanced clinical stage, lymph node metastasis and patient poor prognosis

(2008) L.-X. Yan et al.   RNA